Proactive Investors - Run By Investors For Investors

Redx Pharma CEO focused on driving fibrosis and oncology assets into the clinic

Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), caught up with Proactive London's Andrew Scott to discuss the group's preliminary results to September 2018 as well as the appointment of a new chief financial officer.

Anson says Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

 
Meet Cardinal Resources Ltd and Legend Mining Ltd at our event, Melbourne , 16 July 2019. Register here »
View full REDX profile View Profile

Redx Pharma Plc Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use